Upcoming Webinars

Visualizing the Benefits of 3D Cell Culture

Join us for this GEN webinar, sponsored by Corning, where our guest presenters will share their experiences with 3D cell culture—from the development of tissue specific spheroids to new imaging modalities.

Proteomics Goes 4D to Enhance Understanding of Clotting Diseases

In this GEN webinar, sponsored by Bruker, our expert panelists will discuss how the timsTOF Pro mass spectrometry (MS) platform combines trapped ion mobility with a quadrupole, collision cell, and a TOF mass analyzer to probe ions at high speeds with on-the-fly fragmentation.

Combatting SARS-CoV-2 Variants: Neutralization Testing from Alpha to Mu

Join this GEN webinar, sponsored by Integral Molecular, to learn how SARS-CoV-2 Reporter Virus Particles (RVPs, pseudotyped viruses) enable researchers to rapidly test neutralization titers of antibodies and vaccinee sera in a safe BSL-2 environment.

On Demand Webinars

GEN 40th Anniversary: Getting the Band Back Together

In celebration of GEN’s 40th year in publishing, TODAY's GEN Live will feature a panel of biotech reporters and scientists who have been covering the bioindustry since the early 1980s.

Analytical Solutions for Cell & Gene Therapy

In TODAY's GEN webinar, sponsored by Waters, our presenters will describe some of the latest analytical methods to determine LNP composition and impurity profiles using LC-MS and LC-ELSD (evaporative light scattering detector) devices. Additionally, we will also learn how LC-MS can be effectively used to determine mRNA 5' capping efficiency.

Uncovering the Secrets of AAV for Improved Cell and Gene Therapies

We are all keenly aware that viruses can negatively impact our lives, but what about viruses that shape our existence and even improve some of its outcomes? In the past several decades, advances in cell and gene therapies have exploded due to innovations with adeno-associated virus (AAV). In this GEN webinar, sponsored by OXGENE, our notable presenter Dr. Ryan Cawood will discuss how TESSA technology enhances both AAV production yields and particle quality by suppressing adenoviral late gene expression.